Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of a new inhaled
sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be
inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate
blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and
eliminated after 14 days of treatment.